Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers
批准号:
10595099
负责人:
Saro Armenian
金额:
$79.82万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-04-01 至 2025-03-31
关键词:
AddressAgeCancer BurdenCancer DetectionCancer SurvivorCancer SurvivorshipCardiovascular systemCaringCellular PhoneClinicalCoupledDermatologicDermatologistDermatologyDetectionDiagnosisE-learningEarly DiagnosisEarly treatmentEducationEducational process of instructingEndocrineEnrollmentEnsureExposure toFaceFutureGeneral PopulationHealth PromotionHematologic NeoplasmsHematological DiseaseHematologyHigh-Risk CancerIndividualKnowledgeLate EffectsLesionLong-Term CareLong-Term SurvivorsMalignant NeoplasmsMeasuresMedicalMorbidity - disease rateNeoplasmsOncologyParticipantPatientsPatternPhysiciansPopulationPreventive carePrimary CarePrimary Care PhysicianPrintingProviderQuality of lifeRadiation exposureRandomizedRecurrenceReportingResearch PriorityRiskRisk FactorsScreening for Skin CancerSelf-ExaminationSkinSkin CancerSkin CarcinomaSurvival RateSurvivorsTechnologyTestingTherapeutic immunosuppressionTimeTransplant RecipientsTreatment-Related CancerUnited States National Institutes of HealthWhole-Body Irradiationadvanced diseasebehavioral outcomecancer diagnosisclinically relevantcomparative effectiveness studyconditioningcostcost effectivedigitalexperiencefollow-upgraft vs host diseasehealth related quality of lifehematopoietic cell transplantationhigh riskimplementation scienceimprovedinnovationmelanomamortalitymultidisciplinaryprevention practiceprimary care providerprimary care settingprogramsresponsescreeningskillssurvivorshiptransplant centerstransplant survivor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY/ABSTRACT
Hematopoietic cell transplantation (HCT) is a curative option for a growing number of patients with hematologic
diseases and malignancies. However, HCT-related factors, such as total body irradiation used for conditioning,
graft-versus-host disease, and prolonged exposure to immunosuppressive therapy, result in very high risk for
subsequent skin cancers. Compared with the general population, HCT survivors are also more likely to develop
skin cancers at a younger age, have advanced disease at presentation, and experience multiple recurrences.
Despite this high burden, less than 20% of long-term HCT survivors report being examined for skin cancer, even
though >90% were seen by their primary care physician (PCPs) in the prior year. In HCT survivors, skin cancers
develop at a time when their follow-up care has largely transitioned from oncology care to the primary care
setting, emphasizing the need to develop innovative strategies that 1) provide HCT survivors with the skills to
conduct effective skin self-examinations, and prompt action from their providers when worrisome lesions are
found; 2) engage PCPs in HCT risk-based screening for skin cancer; and 3) ensure rapid access to dermatologic
exams. Advances in technology, including widespread availability of cell phones and teledermoscopy (remote
expert assessment of a photographed lesion) offer promising opportunities to improve early detection and
treatment of skin cancer. We propose a comparative effectiveness study that will examine the impact of patient
activation and education (PAE), alone or in combination with physician-tailored strategies, on clinically
meaningful behavioral outcomes. We will enroll 720 HCT survivors at a large, diverse HCT center to:
1) Determine the impact of PAE alone or with physician activation (PAE+Phys) on skin cancer screening and
prevention practices at 12 months; and 2) Among PCPs of HCT survivors, determine the impact of a
teledermoscopy e-learning program compared with provision of print materials for identifying suspect lesions.
We hypothesize that compared to PAE, patients randomized to PAE+Phys will report higher rates of thorough
self- and provider skin exam, shorter time to referral of suspicious lesions, and improved quality of life; compared
to print materials alone, physicians randomized to teledermoscopy e-learning will have greater recognition of
suspect lesions and more appropriate, cost-effective referral patterns. Our multi-disciplinary team will: 1)
establish the efficacy of PAE, and the relative benefit of physician activation; 2) inform the practice of skin cancer
screening using innovative mobile strategies that are readily applicable in the clinical setting; and 3) identify
facilitators of and barriers to appropriate delivery of survivorship-focused preventive care for long-term HCT
survivors. Information obtained from the current study can be used to develop strategies for management of
other late effects (e.g. cardiovascular, endocrine) in HCT survivors in the primary care setting, and to improve
skin cancer screening in other high-risk (e.g. radiation-exposed) cancer survivor populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Remote monitoring of cardiac function in childhood cancer survivors
-
批准号:10274206
-
项目类别:
-
资助金额:$22.23万
-
财政年份:2021
-
负责人:Saro Armenian
-
依托单位:
Remote monitoring of cardiac function in childhood cancer survivors
-
批准号:10456314
-
项目类别:
-
资助金额:$17.44万
-
财政年份:2021
-
负责人:Saro Armenian
-
依托单位:
Technology-Enabled Activation of Skin Cancer Screening for Hematopoietic Cell Transplantation Survivors and their Primary Care Providers
-
批准号:10375440
-
项目类别:
-
资助金额:$80.66万
-
财政年份:2020
-
负责人:Saro Armenian
-
依托单位:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
-
批准号:10092215
-
项目类别:
-
资助金额:$70.89万
-
财政年份:2020
-
负责人:Saro Armenian
-
依托单位:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
-
批准号:10558477
-
项目类别:
-
资助金额:$70.05万
-
财政年份:2020
-
负责人:Saro Armenian
-
依托单位:
Cardiovascular reserve capacity in survivors of hematopoietic cell transplantation
-
批准号:10369583
-
项目类别:
-
资助金额:$69.01万
-
财政年份:2020
-
负责人:Saro Armenian
-
依托单位:
Reducing risk of Anthracycline-related heart failure after childhood cancer
-
批准号:9103021
-
项目类别:
-
资助金额:$66.99万
-
财政年份:2015
-
负责人:Saro Armenian
-
依托单位:
Reducing risk of Anthracycline-related heart failure after childhood cancer
-
批准号:8941193
-
项目类别:
-
资助金额:$72.51万
-
财政年份:2015
-
负责人:Saro Armenian
-
依托单位:
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
-
批准号:8569676
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2013
-
负责人:Saro Armenian
-
依托单位:
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
-
批准号:8689987
-
项目类别:
-
资助金额:$15.55万
-
财政年份:2013
-
负责人:Saro Armenian
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: